177 related articles for article (PubMed ID: 21282502)
1. Growth factor therapy and autologous lymph node transfer in lymphedema.
Lähteenvuo M; Honkonen K; Tervala T; Tammela T; Suominen E; Lähteenvuo J; Kholová I; Alitalo K; Ylä-Herttuala S; Saaristo A
Circulation; 2011 Feb; 123(6):613-20. PubMed ID: 21282502
[TBL] [Abstract][Full Text] [Related]
2. Lymph node transfer and perinodal lymphatic growth factor treatment for lymphedema.
Honkonen KM; Visuri MT; Tervala TV; Halonen PJ; Koivisto M; Lähteenvuo MT; Alitalo KK; Ylä-Herttuala S; Saaristo AM
Ann Surg; 2013 May; 257(5):961-7. PubMed ID: 23013803
[TBL] [Abstract][Full Text] [Related]
3. VEGF-C and VEGF-C156S in the pro-lymphangiogenic growth factor therapy of lymphedema: a large animal study.
Visuri MT; Honkonen KM; Hartiala P; Tervala TV; Halonen PJ; Junkkari H; Knuutinen N; Ylä-Herttuala S; Alitalo KK; Saarikko AM
Angiogenesis; 2015 Jul; 18(3):313-26. PubMed ID: 26018927
[TBL] [Abstract][Full Text] [Related]
4. Growth factor therapy and autologous lymph node transfer in lymphedema.
Hartiala P; Saaristo AM
Trends Cardiovasc Med; 2010 Nov; 20(8):249-53. PubMed ID: 22433650
[TBL] [Abstract][Full Text] [Related]
5. [A preliminary study on vascular endothelial growth factor C gene modified lymph node transplantation in promoting proliferation of lymphatic endothelial cells].
Lu N; Zhang Y; Feng Z; Qi F
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2013 May; 27(5):619-23. PubMed ID: 23879104
[TBL] [Abstract][Full Text] [Related]
6. Growth factor therapy and lymph node graft for lymphedema.
Tervala TV; Hartiala P; Tammela T; Visuri MT; Ylä-Herttuala S; Alitalo K; Saarikko AM
J Surg Res; 2015 Jun; 196(1):200-7. PubMed ID: 25777822
[TBL] [Abstract][Full Text] [Related]
7. [Experimental study of gene therapy with human vascular endothelial growth factor-c in lymphedema].
Zhou JG; Hu XQ; Cao WG; Li SL; Cheng KX; Liu NF; Zhang DS; Wu JJ; Yin LM; Liu DL
Zhonghua Zheng Xing Wai Ke Za Zhi; 2007 Nov; 23(6):519-21. PubMed ID: 18269031
[TBL] [Abstract][Full Text] [Related]
8. [Experimental studies of VEGF-C gene for the treatment of chronic obstructive lymphedema in mouse tail model].
Hu XQ; Jiang ZH; Liu NF
Zhonghua Zheng Xing Wai Ke Za Zhi; 2008 May; 24(3):207-11. PubMed ID: 18717357
[TBL] [Abstract][Full Text] [Related]
9. Extracorporeal shock wave therapy combined with vascular endothelial growth factor-C hydrogel for lymphangiogenesis.
Kim IG; Lee JY; Lee DS; Kwon JY; Hwang JH
J Vasc Res; 2013; 50(2):124-33. PubMed ID: 23208012
[TBL] [Abstract][Full Text] [Related]
10. Phase 1 Lymfactin
Hartiala P; Suominen S; Suominen E; Kaartinen I; Kiiski J; Viitanen T; Alitalo K; Saarikko AM
J Plast Reconstr Aesthet Surg; 2020 Sep; 73(9):1612-1621. PubMed ID: 32513642
[TBL] [Abstract][Full Text] [Related]
11. Microlymphatic surgery for the treatment of iatrogenic lymphedema.
Becker C; Vasile JV; Levine JL; Batista BN; Studinger RM; Chen CM; Riquet M
Clin Plast Surg; 2012 Oct; 39(4):385-98. PubMed ID: 23036289
[TBL] [Abstract][Full Text] [Related]
12. Molecular control of lymphatic metastasis.
Achen MG; Stacker SA
Ann N Y Acad Sci; 2008; 1131():225-34. PubMed ID: 18519975
[TBL] [Abstract][Full Text] [Related]
13. Improved regeneration of autologous transplanted lymph node fragments by VEGF-C treatment.
Sommer T; Buettner M; Bruns F; Breves G; Hadamitzky C; Pabst R
Anat Rec (Hoboken); 2012 May; 295(5):786-91. PubMed ID: 22419614
[TBL] [Abstract][Full Text] [Related]
14. Expression of VEGF-C and VEGF-D as significant markers for assessment of lymphangiogenesis and lymph node metastasis in non-small cell lung cancer.
Feng Y; Wang W; Hu J; Ma J; Zhang Y; Zhang J
Anat Rec (Hoboken); 2010 May; 293(5):802-12. PubMed ID: 20225197
[TBL] [Abstract][Full Text] [Related]
15. Transfection of human hepatocyte growth factor gene ameliorates secondary lymphedema via promotion of lymphangiogenesis.
Saito Y; Nakagami H; Morishita R; Takami Y; Kikuchi Y; Hayashi H; Nishikawa T; Tamai K; Azuma N; Sasajima T; Kaneda Y
Circulation; 2006 Sep; 114(11):1177-84. PubMed ID: 16952986
[TBL] [Abstract][Full Text] [Related]
16. VEGF-D is the strongest angiogenic and lymphangiogenic effector among VEGFs delivered into skeletal muscle via adenoviruses.
Rissanen TT; Markkanen JE; Gruchala M; Heikura T; Puranen A; Kettunen MI; Kholová I; Kauppinen RA; Achen MG; Stacker SA; Alitalo K; Ylä-Herttuala S
Circ Res; 2003 May; 92(10):1098-106. PubMed ID: 12714562
[TBL] [Abstract][Full Text] [Related]
17. Tumor-induced lymphangiogenesis: a target for cancer therapy?
Thiele W; Sleeman JP
J Biotechnol; 2006 Jun; 124(1):224-41. PubMed ID: 16497404
[TBL] [Abstract][Full Text] [Related]
18. Adenoviral catheter-mediated intramyocardial gene transfer using the mature form of vascular endothelial growth factor-D induces transmural angiogenesis in porcine heart.
Rutanen J; Rissanen TT; Markkanen JE; Gruchala M; Silvennoinen P; Kivelä A; Hedman A; Hedman M; Heikura T; Ordén MR; Stacker SA; Achen MG; Hartikainen J; Ylä-Herttuala S
Circulation; 2004 Mar; 109(8):1029-35. PubMed ID: 14967735
[TBL] [Abstract][Full Text] [Related]
19. Lymphangiogenesis and angiogenesis in bladder cancer: prognostic implications and regulation by vascular endothelial growth factors-A, -C, and -D.
Miyata Y; Kanda S; Ohba K; Nomata K; Hayashida Y; Eguchi J; Hayashi T; Kanetake H
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):800-6. PubMed ID: 16467091
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3.
Mäkinen T; Jussila L; Veikkola T; Karpanen T; Kettunen MI; Pulkkanen KJ; Kauppinen R; Jackson DG; Kubo H; Nishikawa S; Ylä-Herttuala S; Alitalo K
Nat Med; 2001 Feb; 7(2):199-205. PubMed ID: 11175851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
